KR970706490A - 중추신경계 기능 및 기능부전의 실험실 모델(in vitro models of cns function and dysfunction) - Google Patents

중추신경계 기능 및 기능부전의 실험실 모델(in vitro models of cns function and dysfunction)

Info

Publication number
KR970706490A
KR970706490A KR1019970701845A KR19970701845A KR970706490A KR 970706490 A KR970706490 A KR 970706490A KR 1019970701845 A KR1019970701845 A KR 1019970701845A KR 19970701845 A KR19970701845 A KR 19970701845A KR 970706490 A KR970706490 A KR 970706490A
Authority
KR
South Korea
Prior art keywords
disease
biological agent
cells
cell
culture medium
Prior art date
Application number
KR1019970701845A
Other languages
English (en)
Inventor
웨이스 사무엘
레이놀드스 브렌트
Original Assignee
스코트 디. 코르맥
뉴로스피어스 홀딩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스코트 디. 코르맥, 뉴로스피어스 홀딩스 리미티드 filed Critical 스코트 디. 코르맥
Publication of KR970706490A publication Critical patent/KR970706490A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

중식되고 있거나 중식된 신경간세포 및 이들의 후손세포가 신경발달 및 기능화의 연구, 및 새로운 치료 및 그밖의 생물학적 작용제의 CNS 효과를 측정하기 위한 CNS 모델 시스템을 생산하는데 사용된다. 신경간세포는 출생전후의 환자로부터의 소량의 정상 또는 질병감염된 CNS 조직에서 얻는다. 본 발명은 다양성이 한정되도록 클론적으로 유도될수 있는 다량의 조직이 소량의 CNS 조지으로부터 생성되게 한다. 본 발명에서는 신경 간세포의 분화된 후손세포가 뉴우런, 성상세포 및 회소돌기아교세포를 포함한 다양한 형태의 CNS 세포를 포함하도록 하는 CNSS 모델 시스템이 기재되어 있다. 신경 또는 그밖의 생물학적 작용제의 효과를 스크리닝하고, 다역가 신경간세포 및 정상 또는 질병 감염된 공여체의 간세포 유도된 후손세포에서의 유전자 발현을 분석하는 것은 본 발명의 모델 시스템을 이용하여 수행할 수 있다.

Description

중추신경계 기능 및 기능부전의 실험실 모델(IN VITRO MODELS OF CNS FUNCTION AND DYSFUNCTION)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 표피 성장인자(EGF) 반응성 세포의 증식을 도시한 도면, 제2도는 단일의 EGF-발생 구체로부터 뉴우런, 성상세포 및 회소돌기아교세포로 세포분화가 일어나는 것을 도시한 도면, 제3도는 성상세포 선조체와 함께 배양된 신경구체(neurosphere)의 표지화를 도시한 도면, 제4도는 뇌로부터 유래된 신경 항성인자(BDNF)의 존재하에 1개의 신경구체로부터 제조된 뉴우런 수적 증가를 나타낸 도면, 제5도는 BDNF의 존재하에 증강된 신경처리 과정의 부산물을 도시한 도면, 제6도는 1개의 신경구체내에서 선택된 수의 세포에 의한 BDNF에 대한 반응을 도시한 도면.

Claims (36)

  1. a) 하나 이상의 다역가 간세포를 함유하는 포유동물 신경조직을 분리하는 단계; b) 하나 이상의 성장인자를 함유하는 배양배지에서 다역가 간세포를 증식시켜 증식된 전구세포의 배양물을 얻는 단계; c) 증식된 전구 세포를 생물학적 작용제와 접촉시키는 단계; 및 d) 전구세포에 대한 생물학적 작용제의 효과를 측정하는 단계를 포함하여, 신경 전구 세로에 대한 하나 이상의 생물학적 작용제의 효과를 측정하는 방법.
  2. 제1항에 있어서, 성장인자가 EGF, bFGF, 및 EFG와 bFGF의 복합물로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  3. 제1항에 있어서, 배양배지가 한정됨을 특징으로 하는 방법.
  4. 제1항에 있어서, 포유동물 신경조직을 출생 후의 포유동물에서 얻음을 특징으로 하는 방법.
  5. 제1항에 있어서, 포유동물 신경조직을 사람 공여체에서 얻음을 특징으로 하는 방법.
  6. 제5항에 있어서, 사람의 신경질환 또는 질병을 앓고 있음을 특징으로 하는 방법.
  7. 제6항에 있어서, 생물학적 작용제가 신경질환 또는 질병에 효능적인 치료제임을 특징으로 하는 방법.
  8. 제7항에 있어서, 신경질환 또는 질병이 알쯔하이머 질환, 파킨슨 질환, 및 다운 증후군으로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  9. 제1항 또는 제6항에 있어서, 단계 (d)의 효과가 생물학적 작용제와 접촉되는 단계(c)의 증식된 전구세포의 유전자 라이브레리를 생물학적 작용제와 접촉되지 않은 단계(b)의 증식된 전구세포의 유전자 라이브레리와 비교함으로써 측정됨을 특징으로 하는 방법.
  10. a) 하나 이상의 다역가 간세포를 함유하는 포유동물 신경조직을 분리하는 단계; b) 하나 이상의 성장인자를 함유하는 제1배양배지에서 다역가 간세포를 증식시켜 증식된 전구세포의 배양물을 얻는 단계; c) 증식된 전구세포를 유도하여 생물학적 작용제의 존재하에 제2배양배지에서 분화시키는 단계; 및 d) 전구세포의 분화에 대한 생물학적 작용제의 효과를 측정하는 단계를 포함하여, 신경 전구세포에 대한 하나 이상의 생물학적 작용제의 효과를 측정하는 방법.
  11. 제10항에 있어서, 성장인자가 EGF, bFGF, 및 EFG와 bFGF의 복합물로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  12. 제10항에 있어서, 제1배양배지가 한정됨을 특징으로 하는 방법.
  13. 제10항에 있어서, 포유동물 신경조직을 소아 또는 성숙한 포유동물에서 얻음을 특징으로 하는 방법.
  14. 제10항에 있어서, 포유동물 신경조직을 사람 공여체에서 얻음을 특징으로 하는 방법.
  15. 제14항에 있어서, 사람의 신경질환 또는 질병을 앓고 있음을 특징으로 하는 방법.
  16. 제15항에 있어서, 생물학적 작용제가 신경질환 또는 질병에 효능적인 치료제임을 특징으로 하는 방법.
  17. 제16항에 있어서, 신경질환 또는 질병이 알쯔하이머 질환, 파킨슨 질환, 및 다운 증후군으로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  18. 제10항 또는 제15항에 있어서, 단계 (d)의 효과가 생물학적 작용제와 접촉되는 단계(c)의 증식된 전구세포의 유전자 라이브레리를 생물학적 작용제와 접촉되지 않은 단계(b)의 증식된 전구세포의 유전자 라이브레리와 비교함으로써 측정됨을 특징으로 하는 방법.
  19. 제10항에 있어서, 증식된 전구세포를 유도하고 영양인자의 존재하에 분화시켜 분화된 세포의 표현형을 조작하는 것을 특징으로 하는 방법.
  20. 제10항에 있어서, 제2배양배지가 신경교 세포 공급자-세포층을 포함함을 특징으로 하는 방법.
  21. a) 하나 이상의 다역가 간세포를 함유하는 포유동물 신경조직을 분리하는 단계; b) 하나 이상의 성장인자를 함유하는 제1배양배지에서 다역가 간세포를 증식시켜 증식된 전구세포의 배양물을 얻는 단계; c) 분화된 신경세포의 배양물을 얻도록 증식된 전구세포를 유도하여 제2배양배지에서 분화시키는 단계; d) 분화된 신경세포를 생물학적 작용제와 접촉시키는 단계; 및 e) 분화된 신경세포에 대한 생물학적 작용제의 효과를 측정하는 단계를 포함하여, 신경 전구세포에 대한 하나 이상의 생물학적 작용제의 효과를 측정하는 방법.
  22. 제21항에 있어서, 성장인자가 EGF, bFGF, 및 EFG와 bFGF의 복합물로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  23. 제21항에 있어서, 배양배지가 한정됨을 특징으로 하는 방법.
  24. 제21항에 있어서, 포유동물 신경조직을 소아 또는 성인으로부터 얻음을 특징으로 하는 방법.
  25. 제21항에 있어서, 포유동물 신경조직을 사람 공여체에서 얻음을 특징으로 하는 방법.
  26. 제25항에 있어서, 사람의 신경질환 또는 질병을 앓고 있음을 특징으로 하는방법.
  27. 제26항에 있어서, 생물학적 작용제가 신경질환 또는 질병에 효능적인 치료제임을 특징으로 하는 방법.
  28. 제26항에 있어서, 신경질환 또는 질병이 알쯔하이머 질환, 파킨슨 질환, 및 다운 증후군으로 이루어진 군중에서 선택됨을 특징으로 하는 방법.
  29. 제21항 또는 제26항에 있어서, 단계 (e)의 효과가 생물학적 작용제와 접촉되는 단계(d)에서의 분화된 신경세포의 유전자 라이브레리를 생물학적 작용제와 접촉되지 않은 단계(c)에서의 분화된 신경 세포의 유전자 라이브레리와 비교함으로써 측정됨을 특징으로 하는 방법.
  30. 제21항에 있어서, 증식된 전구세포를 유도하고 영양인자의 존재하에 분화시켜 분화된 세포의 표현형을 조작함을 특징으로 하는 방법.
  31. 제21항에 있어서, 제2의 배양배지가 신경교 세포 공급자-세포층을 포함함을 특징으로 하는 방법.
  32. 신경세포로부터 제조된 cDNA 라이브레리.
  33. 제32항에 있어서, 신경세포가 신경 간세포임을 특징으로 하는 cDNA 라이브레리.
  34. 제32항에 있어서, 신경세포가 전구세포임을 특징으로 하는 cDNA 라이브레리.
  35. 제32항에 있어서, 신경세포가 뉴우런, 성상세포 및 희소돌기아교세포로 이루어진 군중에서 선택된 분화된-세포임을 특징으로 하는 cDNA 라이브레리.
  36. 제32항에 있어서, 신경세포가 신경질환 또는 질병을 앓고 있는 사람으로부터 유도됨을 특징으로 하는 cDNA 라이브레리.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701845A 1994-09-23 1995-09-22 중추신경계 기능 및 기능부전의 실험실 모델(in vitro models of cns function and dysfunction) KR970706490A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31109994A 1994-09-23 1994-09-23
US48189395A 1995-06-07 1995-06-07
US08/481,893 1995-06-07
US08/311,099 1995-06-07
PCT/CA1995/000542 WO1996009543A1 (en) 1994-09-23 1995-09-22 In vitro models of cns function and dysfunction

Publications (1)

Publication Number Publication Date
KR970706490A true KR970706490A (ko) 1997-11-03

Family

ID=26977743

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701845A KR970706490A (ko) 1994-09-23 1995-09-22 중추신경계 기능 및 기능부전의 실험실 모델(in vitro models of cns function and dysfunction)

Country Status (14)

Country Link
EP (2) EP1130394B1 (ko)
JP (1) JPH10505754A (ko)
KR (1) KR970706490A (ko)
AT (2) ATE345496T1 (ko)
AU (1) AU714837B2 (ko)
CA (1) CA2200709A1 (ko)
DE (2) DE69535300T2 (ko)
DK (2) DK1130394T3 (ko)
ES (1) ES2167461T3 (ko)
FI (1) FI971168A (ko)
MX (1) MX9702126A (ko)
NO (1) NO971245L (ko)
PT (1) PT783693E (ko)
WO (1) WO1996009543A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
DE60035191T2 (de) * 1999-05-03 2008-06-19 Neuro Therapeutics Ab Materialien und methoden zur entwicklung von dopaminergen neuronen
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
US7514259B2 (en) 2000-02-11 2009-04-07 Schepens Eye Research Institute Isolation and transplantation of retinal stem cells
EP1271145A1 (en) * 2001-06-25 2003-01-02 Cardion AG Methods and cell populations for identifying and validating genomic targets, and for drug screening
CA2461290C (en) 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US7129034B2 (en) 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
US20050019801A1 (en) * 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
IN2014CN03629A (ko) 2004-11-17 2015-09-04 Neuralstem Inc
EP2077092A3 (en) * 2007-10-29 2009-10-21 Taipei Veterans General Hospital System and Methods for Screening or Analyzing Targets
GB0815224D0 (en) * 2008-08-20 2008-09-24 Eisai London Res Lab Ltd Screening assay
US9540611B2 (en) 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
EP3492586B1 (en) 2012-02-17 2024-04-17 Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
CA2964927C (en) 2014-10-20 2019-07-30 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
JP6844953B2 (ja) * 2015-04-22 2021-03-17 公益財団法人東京都医学総合研究所 アルツハイマー病研究を標的にしたグリア細胞システム
CN105861482B (zh) * 2016-04-05 2019-10-11 中国科学院广州生物医药与健康研究院 体外细胞疾病模型及其制备方法
EP3609511A4 (en) * 2017-04-13 2020-12-23 The Board of Trustees of the Leland Stanford Junior University PERSONALIZED 3D NEURONAL CULTURE SYSTEM FOR GENERATING HUMAN OLIGODENDROCYTE AND STUDYING MYELINIZATION IN VITRO

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
WO1991009936A1 (en) * 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
ES2198404T5 (es) * 1991-07-08 2008-05-01 Neurospheres Holdings Ltd. Celulas progenitoras neurales que responden a factor de crecimiento y que se pueden hacer proliferar in vitro.
DK0669973T4 (da) * 1992-10-28 2007-08-27 Neurospheres Holdings Ltd Biologiske faktorer og neurale stamceller

Also Published As

Publication number Publication date
FI971168A0 (fi) 1997-03-20
PT783693E (pt) 2002-04-29
EP1130394B1 (en) 2006-11-15
WO1996009543A1 (en) 1996-03-28
DE69535300D1 (de) 2006-12-28
ATE208495T1 (de) 2001-11-15
CA2200709A1 (en) 1996-03-28
AU3515295A (en) 1996-04-09
MX9702126A (es) 1997-06-28
FI971168A (fi) 1997-03-20
AU714837B2 (en) 2000-01-13
NO971245D0 (no) 1997-03-18
DK1130394T3 (da) 2007-01-08
DE69535300T2 (de) 2007-06-06
DK0783693T3 (da) 2002-01-14
EP0783693A1 (en) 1997-07-16
ATE345496T1 (de) 2006-12-15
NO971245L (no) 1997-03-18
EP0783693B1 (en) 2001-11-07
DE69523771D1 (de) 2001-12-13
DE69523771T2 (de) 2002-08-01
EP1130394A1 (en) 2001-09-05
ES2167461T3 (es) 2002-05-16
JPH10505754A (ja) 1998-06-09

Similar Documents

Publication Publication Date Title
KR970706490A (ko) 중추신경계 기능 및 기능부전의 실험실 모델(in vitro models of cns function and dysfunction)
Ahmad et al. In vitro analysis of a mammalian retinal progenitor that gives rise to neurons and glia
Schwartz et al. Isolation and characterization of neural progenitor cells from post‐mortem human cortex
Reubinoff et al. Neural progenitors from human embryonic stem cells
Reynolds et al. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell
JP4023822B2 (ja) ドーパミン作動性細胞のインビトロ誘導
Kilpatrick et al. Cloned multipotential precursors from the mouse cerebrum require FGF-2, whereas glial restricted precursors are stimulated with either FGF-2 or EGF
Burnstein et al. Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson’s disease
Roussa et al. GDNF promotes neuronal differentiation and dopaminergic development of mouse mesencephalic neurospheres
KR950703639A (ko) 신경 간세포를 사용하는 재수초화(remyelination using neural stem cells)
FI935929A0 (fi) Ny vaext regulerande faktor i stamcellen som foermaor foeroeka in vitro
KR970707272A (ko) 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation)
CA2307017A1 (en) Erythropoietin-mediated neurogenesis
Young et al. Behavior of embryonic rat cerebral cortical stem cells on the PVA and EVAL substrates
Seidman et al. Isolation, cloning and characterization of a putative type-1 astrocyte cell line
Baetge Neural stem cells for CNS transplantation
Asou et al. CNS myelinogenesis in vitro: time course and pattern of rat oligodendrocyte development
An et al. Differentiation of rat neural stem cells and its relationship with environment
Walczak et al. Long-term cultured human umbilical cord neural-like cells transplanted into the striatum of NOD SCID mice
Li et al. Spontaneous expression of neural phenotype and NGF, TrkA, TrkB genes in marrow stromal cells
Li et al. Induction of functional recovery by co-transplantation of neural stem cells and Schwann cells in a rat spinal cord contusion injury model
Kim et al. Forskolin promotes astroglial differentiation of human central neurocytoma cells
Feng et al. Biological properties of neural progenitor cells isolated from the hippocampus of adult cynomolgus monkeys
Nakamura et al. Mimicking the neurotrophic factor profile of embryonic spinal cord controls the differentiation potential of spinal progenitors into neuronal cells
Ostenfeld et al. Mouse epidermal growth factor-responsive neural precursor cells increase the survival and functional capacity of embryonic rat dopamine neurons in vitro

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid